Immunohistochemical tumoral markers in infiltrating ductal mammary carcinoma;Marcadores tumorales inmunohistoquímicos en carcinoma ductal infiltrante de la mama

Revista Medica de Chile

Volumn 126, Issue 10, 1998, Pages 1216-1223

  Gallegos A , Marcela ^a   González B, Sergio ^a   León R, Augusto ^a   Claure S, Raúl ^a   Goñi E, Ignacio ^a   Andrade M, Leonardo ^a,b   Duarte, Ignacio G ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b Tecnólogo Médico ^*

Author keywords

Mammary neoplasms; Receptors estrogen; Receptors progesterone; Tumor markers biochemical

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR MARKER;

ADULT; AGE; AGED; ANIMAL; ARTICLE; BREAST TUMOR; CANCER STAGING; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032175689     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. OSBORNE CK, YOCHOMOWITZ MG, KNIGHT WA, MCGUIRE WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46: 2884-8.
2. RUDER AM, LUBIN F, WAX Y, GEIER A, ALFUNDARY E, CHETRIT A. Estrogen and progesterone receptors in breast cancer patients: epidemiologic characteristics and survival differences. Cancer 1989; 64: 196-202.
3. TAVASSOLI FA. Pathology of the breast. Norwalk: Appleton & Lange, 1992; cap. 2: 25-62.
4. NOMURA Y, MIURA S, KOYAMA H, ENOMOTO K, KASUMI F, YAMAMOTO H ET AL. Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer: a univariate and multivariate analysis of 3089 Japanese patients with breast cancer from the Study Group for the Japanese Breast Cancer Society on Hormone Receptors and Prognosis in Breast Cancer. Cancer 1992; 69: 153-64.
5. MCCLELLAND RA, FINLAY P, WALKER KJ, NICHOLSON D, ROBERTSON JFR, BLAMEY RW ET AL. Automated quantitation of immunocytochemically localized estrogen receptor in human breast cancer. Cancer Res 1990; 50: 3545-50.
6. BEZWODA WR, ESSER JD, DANCEY R, KESSEL Y, RAD MM, LANGE M. The value of estrogen and progesterone receptor determinations in advanced breast cancer: estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer 1991; 68: 867-72.
7. HOWELL A, BARNES DM, HARLAND RNL, REDFORD J, BRAMWELL VHC, WILKINSON MJS ET AL. Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet 1984; 1, 588-91.
8. PICHON MF, PALLUD C, BRUNET M, MILGROM E. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res 1980; 40: 3357-60.
9. CARSON DA, LOIS A. Progresión del cáncer y p53. Lancet (Ed. Esp.) 1996; 28: 198-200.
10. FISHER DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78: 539-42.
11. RILKE F, COLNAGHI MI, CASCINELLI N, ANDREOLA S, BALDINI MT, BUFALINO R ET AL. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991; 49: 44-9.
12. BACUS SS, RUBY SG, WEINBERG DS, CHIN D, ORTIZ R, BACUS JW. HER-2/neu oncogene expression and proliferation in breast cancer. Am J Pathol 1990; 137: 103-11.
13. SLAMON DJ, CLARK GM, WONG SG, LEVINE WJ, ULLRICH A, MCGUIRE WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
14. VAN DE VIJVER MJ, PETERSE JL, MOOR WJ, WISMAN P, LOMANS J, DALESIO ET AL. Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988; 319: 1239-45.
15. TESCH M, SHAWWA A, HENDERSON R. Immunohistochemical determination of estrogen and progesterone receptor status in breast cancer. Am J Clin Pathol 1993; 99: 8-12.
16. ROA JC, BAEZA R, ROMEO E, ANDRADE L, FORADORI A, GONZÁLEZ S. Cáncer de la mama: comparación entre la determinación bioquímica e inmunohistoquímica de los receptores de estrógeno. Rev Méd Chile 1996; 124: 307-12.
17. AZZOPARDI JG, CHEPICK OF, HARTMANN WH, JAFAREY NA, LLOMBART-BOSCH A, OZELLO L ET AL. The World Health Organization histological typing of breast tumors-2nd edition. Am J Clin Pathol 1982; 78: 806-16.
18. HENSON EH, OBERMAN HA, HUTTER RVP. Practice protocol for the examination of specimens removed from patients with cancer of the breast. Arch Pathol Lab Med 1997; 121: 27-33.
19. ELSTON CW, ELLIS JO. Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a long study with long-term follow up. Histopathology 1991; 19: 403-10.
20. MCDIVITT RW, STEWART FW, BERG JW. Tumors of the breast. Atlas of tumor pathology, 2nd series. Bethesda. Armed Forces Institute of Pathology, 1968.
21. BLOOM HJ, RICHARDSON WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359-77.
22. HENSON DE. The histological grading of neoplasma. Arch Pathol Lab Med 1988; 112: 1091-6.
23. LE DOUSSAL V, TUBIANA-HULIN M, FRIEDMAN S, HACENE K, SPYRATOS F, BRUNET M. Prognostic-value of histologic grade nuclear components of Scarff-Bloom-Richardson: an improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989; 64: 1914-21.
24. LESSER ML, ROSEN PP, SENIE RT, DUTHIE K, MENÉNDEZ-BOTET C, SCHWARTZ MK. Estrogen and progesterone receptors in breast carcinoma: correlations with epidemiology and pathology. Cancer 1981; 48: 299-309.
25. REINER A, REINER G, SPONA J, SCHEMPER M, HOLZNER JH. Histopathologic characterization of human breast cancer in correlation with estrogen receptor status: a comparison of immunocytochemical and biochemical analysis. Cancer 1988; 61: 1149-54.
26. ROSEN PP, MENÉNDEZ-BOTET CJ, NISSELBAUM JS, URBAN JA, MIKE V, FRACCHIA A ET AL. Pathological review of breast lesions analized for estrogen receptor protein. Cancer Res 1975; 35: 3187-94.
27. ROSEN PP, LESSER ML, ARROYO CD, CRANOR M, BORGEN P, NORTON L. Immunohistochemical detection of HER-2/neu in patients with axilary lymph node negative breast cancer: a study of epidemiologic risk factors, histologic features, and prognosis. Cancer 1995; 75: 1320-6.
28. ROSEN PP. Biological markers of prognosis. En: Rosen's Breast Pathology, Philadelphia: Lippincott Raven, 1997; 295-320.
29. DAVIDOFF AM, KERNS BM, IGLEHART JD, MARKS JR. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 1991; 51: 2605-10.
30. WALKER RA, DEARING SJ, LANE DP, VARLEY JM. Expression of p53 protein in infiltrating and in situ breast carcinoma. J Pathol 1991; 165: 203-11.
31. MAZARS R, SPINARDI L, BENCKEIKH M, SIMONI-LAFONTAINE J, JEANTEUR P, THEILLET C. p53 mutations ocurr in aggressive breast cancer. Cancer Res 1992; 52: 3918-23.
32. BARBARESCHI M, LEONARDI E, MAURI FA, SERIO G, DAUA PALMA P. p53 and c-erbB-2 protein expression in breast carcinoma: an immunohistochemical study including correlation with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 1992; 98: 408-18.
33. THOU AD, SCHWARTZ LH, KOERNEK FC, EDGERTON SM, SKATES SJ, YIN S ET AL. Analysis of c-erbD-2 expression in breast carcinomas with clinical follow-up. Cancer Res 1989; 49: 7147-52.
34. SLAMON DJ, GODOLPHIN W, JONES LA, HOLT JA, WONG SG, KEITH DE ET AL. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
35. WRIGHT C, ANGUS b, NICHOLSON S, SAINSBURY JRC, CAIRNS J, GULLICK WJ ET AL. Expression of c-erbD-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989; 49: 2087-90.
36. VAN DE VIVJER M, VAN DE BERSSELAAK R, DEVILEE P, CORNELISSE C, PETERSE J, NUSSE R. Amplification of the neu(c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 1987; 7: 2019-23.
37. BORG A, TANDON AK, SIGURDSSON H, CLARK GM, FERNÖ M, FUQUA SAW ET AL. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; 50: 4332-7.
38. HEINTZ NH, LESLIE KO, ROGERS LA, HOWARD PL. Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med 1990; 114: 160-3.
39. PATERSON MC, DIETRICH KD, DANYLUK J, PATERSON AHG, LEES AW, JAMIL N ET AL. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991; 51: 556-67.
40. CLARK G, MCGUIRE WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991; 51: 944-8.